Université de Montreal has identified new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer, inflammatory and immunological disorder.
Hangzhou Institute of Medicine Chinese Academy of Sciences has patented new nitrogen-containing heteroaryl compounds acting as CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
A recent Antelope Therapeutics SAS patent describes new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting canAg (CA242) mucin glycoepitope covalently linked to exatecan designed for use in the treatment of cancer.
CSPC Megalith Biopharmaceutical Co. Ltd. has discovered new antibody-drug conjugates (ADCs) consisting of antibodies targeting CUB domain-containing protein 1 (CDCP1) covalently linked to cytotoxic drugs potentially useful for the treatment of cancer.
Sanofi SA has synthesized new cyclopropane-aryl and vinyloxy-aryl compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors potentially useful for the treatment of cancer.
Pfizer Inc. has synthesized substituted fused heteroaryl lactam compounds acting as dual calcitonin (CALCR; CT-R)/amylin receptor agonists potentially useful for the treatment of obesity and type 2 diabetes.
RSS